China has performed the world’s first commercial brain-computer interface (BCI) implant surgery, advancing its position as a global leader in neurotechnology and setting a new benchmark in the field.
- First commercially approved invasive BCI implant performed in China
- Technology translates brain signals into limb movements for spinal injury patients
- China aims to cultivate global BCI leaders by 2030 with strong government backing
What happened
Chinese surgeons completed the world’s first commercial brain-computer interface implant on a patient with impaired hand mobility caused by a spinal cord injury sustained in a car accident a decade ago. The procedure was successfully carried out at Huashan Hospital in Shanghai and involved implanting a coin-sized chip on the brain’s outer surface, enabling the patient to regain hand motion.
Why it matters
This breakthrough exemplifies China’s rapid advances in neurotechnology and represents the first time an invasive brain-computer interface has transitioned from clinical trials to commercial use globally. The success of this surgery highlights the practical viability of BCI technology to assist patients with neurological impairments and sets a precedent for wider adoption.
What to watch next
The commercial rollout of the NEO device will be closely monitored for its clinical outcomes and market uptake, particularly how it improves quality of life for patients with paralysis or impaired mobility. Expansion into wider clinical applications and broader patient groups will also be a key factor in determining its impact.